Pharmaceutical agent comprising anti-BMP9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia

摘要

The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.

主权项

1. A monoclonal antibody which binds to human BMP9 or an antigen-binding fragment thereof selected from the following (a) to (c):
(a) a monoclonal antibody or an antigen-binding fragment thereof which comprises a heavy chain of an antibody which comprises complementarity determining regions (CDRs) 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs:54 to 56, respectively, and comprises a light chain of an antibody which comprises CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs:57 to 59, respectively, (b) a monoclonal antibody or an antigen-binding fragment thereof which comprises a heavy chain of an antibody which comprises CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs:60 to 62, respectively, and comprises a light chain of an antibody which comprises CDRs 1 to 3 comprising the amino acid sequences represented by SEQ ID NOs:63 to 65, respectively, and (c) an antibody or an antigen-binding fragment thereof which comprises a heavy chain variable region of an antibody comprising the amino acid sequence represented by SEQ ID NO: 128, and comprises a light chain variable region of an antibody comprising the amino acid sequences represented by SEQ ID NO: 132.